REG - PureTech Health PLC - Result of AGM

Puretech HealthAnnouncement

Yesterday 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260610:nRSJ8399Ha&default-theme=true

RNS Number : 8399H  PureTech Health PLC  10 June 2026

10 June 2026

PureTech Health plc

 

Results of Annual General Meeting

 

The Annual General Meeting of PureTech Health plc (LSE: PRTC) ("PureTech" or
the "Company") was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

 

All of the resolutions proposed at the Annual General Meeting were duly passed
by the shareholders on a poll. The results of the poll, incorporating the
proxy votes lodged in advance of the meeting, are set out below.

 

 Resolutions                                                                    For          %      Against     %      Withheld  Total votes cast
 001. To approve the Company's Annual Report and Accounts for year ended 31     148,986,114  99.97  46,392      0.03   10,803    149,032,506
 December 2025
 002. To approve the Directors' Remuneration Report                             142,375,459  95.84  6,172,764   4.16   495,086   148,548,223
 003. To re-elect Ms. Sharon Barber-Lui as a Director                           143,421,622  96.23  5,617,352   3.77   4,335     149,038,974
 004. To re-elect Dr. Michele Holcomb as a Director                             148,415,257  99.58  622,164     0.42   5,888     149,037,421
 005. To re-elect Dr. John LaMattina as a Director                              139,575,205  93.65  9,462,210   6.35   5,894     149,037,415
 006. To re-elect Dr. Robert Langer as a Director                               142,363,975  95.76  6,298,309   4.24   381,025   148,662,284
 007. To elect Mr. Robert Lyne as a Director                                    148,496,575  99.64  539,340     0.36   7,394     149,035,915
 008. To re-elect Ms. Kiran Mazumdar-Shaw as a Director                         122,266,593  82.04  26,769,322  17.96  7,394     149,035,915
 009. To reappoint PricewaterhouseCoopers LLP as Auditors of the Company        148,776,133  99.83  257,001     0.17   10,175    149,033,134
 010. To authorize the Audit Committee to determine the Auditors' remuneration  148,750,724  99.81  286,702     0.19   5,883     149,037,426
 011. To authorize the allotment of shares                                      147,843,913  99.61  578,544     0.39   620,852   148,422,457
 012. To disapply pre-emption rights                                            147,589,781  99.39  905,323     0.61   548,205   148,495,104
 013. To further disapply pre-emption rights for acquisitions and specified     146,398,006  98.59  2,096,790   1.41   548,513   148,494,796
 capital investments.
 014. To authorize market purchase of own shares                                148,852,410  99.90  155,201     0.10   35,698    149,007,611
 015. To authorize general meetings to be called on not less than 14 clear      148,679,278  99.76  360,501     0.24   3,530     149,039,779
 days' notice

 

Notes:

 

(1)  A vote "Withheld" is not a vote in law and is not counted in the
calculation of the votes "For" or "Against" a resolution.

 

(2)  As at June 10, 2026, the number of outstanding shares in the Company was
243,418,190 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all the resolutions at the
AGM.  In accordance with the Company's Articles of Association, on a poll
every member present in person or by proxy has one vote for every share held.

 

(3)  The full text of the resolutions may be found in the Notice of the
Annual General Meeting, copies of which are available on both the Company's
website https://investors.puretechhealth.com/financials-filings/reports and on
the National Storage Mechanism.

 

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving
life to science and transforming innovation into value. We do this through a
proven, capital-efficient R&D model focused on opportunities with
validated pharmacology and untapped potential to address significant patient
needs. This strategy has produced dozens of therapeutic candidates, including
three that have received U.S. FDA approval. By identifying, shaping, and
de-risking these high-conviction assets, and scaling them through dedicated
structures backed by external capital, we accelerate their path to patients
while creating sustainable value for shareholders.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation statements that relate to our expectations around
our therapeutic candidates and approach towards addressing major diseases, our
future prospects, developments, and strategies. The forward-looking statements
are based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2025, filed with the SEC and in
our other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAKKBNABKDOAD



            Copyright 2019 Regulatory News Service, all rights reserved